MS Fingolimod oral treatment is marketed under the brand name Gilenya by its manufacturer, Novartis. It was a landmark approval because at the time, Multiple Sclerosis Fingolimod therapy became the first oral treatment approved and marketed in the United States for relapsing forms of MS.  Then in 2011, the Swiss agency responsible for drug approval (the equivalent to the FDA) gave MS Fingolimod treatment the green light in that country for the relapsing-remitting form of the affliction.  A few months later, similar approval was given in Europe.  Fingolimod seems to enhance the myelination and axonal protection of the nerve cells in oral dosing.  It is the destruction of the myelin sheath that causes the real damage caused by MS so this bears further study but is promising.  MS Fingolimod oral use also seems to have the potential to reduce neurodegeneration and promote endogenous repair of the Central Nervous System.  It …